A Phase 3 interventional study of BF-200 ALA and red light LED lamp and Vehicle and red light LED lamp in Actinic Keratoses, sponsored by Biofrontera Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Biofrontera Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Keratosis, Actinic with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Keratosis, Actinic · United States.
Among the 165 studies in Keratosis, Actinic with a site in United States, this one is the 49th largest by enrollment of the 152 interventional ones that give a count, is one of 5 that started in 2022, is one of 44 in phase 3, and was the 146th registered.
343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.
Browse Keratosis, Actinic studies →16 of the 165 studies in Keratosis, Actinic with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Sun Pharmaceutical Industries Limited · Sites in United States
Ages 18–85
Marissa Lobl · Sites in United States
Ages 18+
Avant Health LLC · Sites in United States
Ages 18+
West Virginia University · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 44 · Phase 3 46 · Phase 4 17
First in 1996; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 73 across the 152 interventional studies, 117 across the 11 observational. Of the 136 that completed or were terminated, 78 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 165 have an industry lead sponsor. The 10 most frequent:
Biofrontera Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Biofrontera Inc. has 1 study filed under Keratosis, Actinic — fewer than ten, so there is no comparison to draw.
7 of the studies in Keratosis, Actinic with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144345Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | 2027-01 |
| NCT07144852Phase 3Sun Pharmaceutical Industries, Inc.Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | 2027-01 |
| NCT07729579Sun Pharmaceutical Industries LimitedAn Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face | 2026-12 |
| NCT05699603University of ArizonaTesting the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients | 2027-02-01 |
| NCT07286318Marissa LoblA Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients | 2027-05-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 165 studies in Keratosis, Actinic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to test the safety, tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light RhodoLED lamps in comparison to vehicle treatment for actinic keratosis (AK) on the extremities and neck/trunk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(cs) medical conditions making implementation of the protocol or interpretation of the study results difficult or impairing subject's safety such as:
Any of the topical treatments defined below within the designated periods prior to screening:
Any use of the systemic treatments within the designated periods prior to screening:
Reassessment of subjects is allowed once in case exclusion criterion 3 is met and eligibility can be achieved within 4 weeks. Reassessment can be done on the day of the actual treatment.
Dosing day exclusion criteria:
At Visit 2 (baseline, PDT-1)
Subjects with sunburn or other possibly confounding skin conditions (e.g., wounds, irritations, bleeding, or skin infections) inside or in close proximity (\< 2 cm distance) to the treatment field. Reassessment of subjects is allowed once if the sunburn or other confounding skin conditions is/are expected to resolve within 2 weeks.
At Visit 4 (PDT-2)
Subjects with sunburn or other possibly confounding skin conditions (e.g., wounds, irritations, bleeding, or skin infections) inside or in close proximity (\< 2 cm distance) to the treatment field. Rescheduling of PDT-2 can be performed once at the earliest possibility after resolution, but rescheduling should not exceed 2 weeks.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical application of BF-200 ALA containing 10% 5-ALA HCl (5-aminolevulinic acid hydrochloride). Red light photodynamic therapy (PDT)
Combination Product: BF-200 ALA and red light LED lamp
Topical application of vehicle to BF-200 ALA containing no active ingredient. Red light photodynamic therapy (PDT)
Combination Product: Vehicle and red light LED lamp
Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT): Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing. PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit.
Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT): Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing. PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit.
Overall Subject Complete Response Rate
Percentage of subjects with all AK target lesions clinically cleared after last PDT
Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)
Overall Subject Complete Response Rate for Subjects With Lesions Treated on Extremities
Percentage of subjects with all AK target lesions on extremities clinically cleared after last PDT
Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)
Overall Subject Complete Response Rate for Subjects With Lesions Treated on Neck/Trunk
Percentage of subjects with all AK target lesions on neck/trunk clinically cleared after last PDT
Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)
Lesion Complete Response Rate
Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after the last PDT, overall and stratified by treatment area and AK severity at baseline (according to Olsen).
Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)
Complete Response Rate for Severe Lesions
Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen; Visit 2) after the last PDT, overall and stratified by treatment area.
Time frame: 12 weeks after the last PDT (Visit 4 or Visit 6)
Subject Complete Response Rate After PDT-1
Percentage of subjects with all AK target lesions clinically cleared after PDT-1, overall and stratified by AK baseline parameters.
Time frame: 12 weeks after PDT-1 (Visit 4)
Lesion Complete Response Rate After PDT-1
Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after PDT-1, overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\]).
Time frame: 12 weeks after PDT-1 (Visit 4)
Complete Response Rate for Severe Lesions After PDT-1
Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen \[mild, moderate, severe\]; Visit 2) after PDT-1, overall and stratified by treatment area.
Time frame: 12 weeks after PDT-1 (Visit 4)
Esthetic Appearance at the End of Treatment Phase Assessed by the Investigator
The esthetic appearance after the last PDT as assessed by the investigator according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.
Time frame: On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)
Esthetic Outcome at the End of Treatment Phase Assessed by the Subject
The esthetic outcome after the last PDT as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.
Time frame: On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)
Satisfaction With PDT at the End of Treatment Phase
Satisfaction with PDT treatment after the last PDT as assessed by the subject; overall and stratified by treatment area. Therefore, subjects were asked if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no).
Time frame: On final visit of the treatment phase, 12 weeks after the last PDT (Visit 4 or Visit 6)
Frequency and Extent of Adverse Events (AEs), AEs of Special Interest (AESIs), Serious AEs (SAEs) and Treatment-emergent AEs (TEAEs) During Treatment Phase
Frequency and extent of AEs, AESIs, SAEs, and TEAEs, overall and stratified by demographics, skin type class (I-III and IV-VI), size of the treatment field, and treatment area. TEAEs were defined as all AEs starting with or after IMP application and within 12 weeks (+ 7 days) after the last PDT, or as related AEs (possibly, probably, or definitely related, or with missing relationship) occurring more than 12 weeks after the last PDT.
Time frame: During entire treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
New Lesions Inside the Treatment Field During Treatment Phase
New lesions: AK, non-melanoma skin cancer \[NMSC, including Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC) or Bowen's Disease (BD)\] or melanoma
Time frame: All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Assessment of Application Site Reactions
Application site reactions (bleeding, burning, discharge, edema, erosion, erythema, exfoliation, hyperalgesia, induration, irritation, paraesthesia, pruritus, pustules, scabbing, or vesicles) were assessed on a 4-point scale: grade 0 = none, grade 1 = mild, grade 2 = moderate, grade 3 = severe. The worst severity across all assessment timepoints and illumination areas is presented.
Time frame: All visits (except screening, Visit 1) throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Application Site Pain During Illumination
Reported by the subjects assessed on an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst imaginable pain); overall and stratified by size of the treatment field and treatment area. The maximum of pain score over all illuminations is shown.
Time frame: During treatment (illumination) on treatment day for PDT-1 (Visit 2, up to 4 weeks after screening) and during treatment (illumination) on treatment day for PDT-2 (Visit 4; if applicable; 12 weeks after PDT-1)
Number of Patients With Significant Changes of Vital Signs
Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\] and changes in pulse rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.
Time frame: All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Number of Patients With Significant Changes in Safety Laboratory
Changes in clinical chemistry, in hematology and urinalysis parameters as defined in the protocol. Findings which differed from reference range and were considered clinically significant were to be reported.
Time frame: All clinical visits throughout the treatment phase, approx. 16 weeks for subjects requiring 1 PDT (until Visit 4) and approx. 28 weeks for subjects with 2 PDTs (until Visit 6)
Number of Patients With Abnormal Findings in Physical Examination
Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.
Time frame: At screening (up to 4 weeks before treatment) and 12 weeks after the last PDT (Visit 4 or Visit 6)
Subject Recurrence Rate
The percentage of subjects with all AK target lesions clinically cleared 12 weeks after the last PDT presenting with at least one recurrent lesion during follow-up, stratified by demographics, study sites, AK baseline parameters
Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)
Lesion Recurrence Rate
The percentage of AK target lesions showing recurrence in follow-up in relation to total number of clinically cleared AK target lesions 12 weeks after last PDT; overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\])
Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)
Recurrence Rate of Severe Lesions
The percentage of severe AK lesions (according to Olsen \[mild, moderate, severe\]) showing recurrence in follow-up in relation to total number of clinically cleared severe AK lesions 12 weeks after last PDT; overall and stratified by treatment area
Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)
Esthetic Appearance at Follow-up Visits Assessed by the Investigator
The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area
Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)
Esthetic Outcome at Follow-up Visits Assessed by the Subject
The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area
Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)
Satisfaction With PDT at Follow-up Visits
Satisfaction with PDT treatment after the last PDT as assessed by the subject via questionnaire, 1. if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no) and 2. how they would rate the PDT treatment in comparison to other treatment modalities, if applicable (better than/ similar/ worse). The treatment modalities should be documented, if applicable); overall and stratified by treatment area
Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)
Any SAE and Relevant AE
Relevant AEs include AEs or conditions affecting skin health in the treatment field which may impair proper assessment of the recurrence rate of the treated AK lesions, or other clinically relevant events at the investigator's discretion as well as any SAE that has occurred since the final visit of the treatment phase (Visit 4 or Visit 6); overall and stratified by demographics and treatment area
Time frame: Entire follow-up duration, approx. 40 weeks
New Lesions Inside the Treatment Field During Follow-up
New lesions: AK, non-melanoma skin cancer \[NMSC, including BCC, SCC or BD\] or melanoma
Time frame: On follow-up Visit 1 (6 months after last PDT) and follow-up Visit 2 (12 months after last PDT)
| Milestone | BF-200 ALA | Vehicle |
|---|---|---|
| Started | 136 | 36 |
| Completed | 119 | 31 |
| Not completed | 17 | 5 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Sponsor request | 1 | 1 |
| Withdrew: Forbidden medication/procedure | 2 | 1 |
| Withdrew: Inability to return for visits | 2 | 0 |
| Withdrew: Noncompliance with study schedule | 0 | 1 |
Percentage of subjects with all AK target lesions clinically cleared after last PDT
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Overall Subject Complete Response Rate | 62 | 6 |
Percentage of subjects with all AK target lesions on extremities clinically cleared after last PDT
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Overall Subject Complete Response Rate for Subjects With Lesions Treated on Extremities | 42 | 3 |
Percentage of subjects with all AK target lesions on neck/trunk clinically cleared after last PDT
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Overall Subject Complete Response Rate for Subjects With Lesions Treated on Neck/Trunk | 20 | 3 |
Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after the last PDT, overall and stratified by treatment area and AK severity at baseline (according to Olsen).
| Lesions | BF-200 ALA | Vehicle |
|---|---|---|
| Overall | 907 | 121 |
| By Treatment Area: Extremities | 700 | 99 |
| By Treatment Area: Neck/Trunk | 207 | 22 |
| By AK Severity at Baseline: Mild | 604 | 71 |
| By AK Severity at Baseline: Moderate | 303 | 50 |
Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen; Visit 2) after the last PDT, overall and stratified by treatment area.
| Severe Lesions | BF-200 ALA | Vehicle |
|---|---|---|
| Overall | 2 | 0 |
| By Treatment Area: Extremities | 2 | 0 |
| By Treatment Area: Neck/Trunk | 0 | 0 |
Percentage of subjects with all AK target lesions clinically cleared after PDT-1, overall and stratified by AK baseline parameters.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Overall | 35 | 4 |
| By Number of AK Target Lesions: 4 - 7 | 17 | 2 |
| By Number of AK Target Lesions: 8 - 11 | 10 | 2 |
| By Number of AK Target Lesions: 12 - 15 | 8 | 0 |
| By Size of Treatment Field: 80 cm² | 9 | 0 |
| By Size of Treatment Field: 160 cm² | 17 | 3 |
| By Size of Treatment Field: 240 cm² | 9 | 1 |
| By Treatment Area: Extremities | 18 | 2 |
| By Treatment Area: Neck/Trunk | 17 | 2 |
The percentage of subjects with all AK target lesions clinically cleared 12 weeks after the last PDT presenting with at least one recurrent lesion during follow-up, stratified by demographics, study sites, AK baseline parameters
Results for this outcome have not been posted.
The percentage of AK target lesions showing recurrence in follow-up in relation to total number of clinically cleared AK target lesions 12 weeks after last PDT; overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\])
Results for this outcome have not been posted.
The percentage of severe AK lesions (according to Olsen \[mild, moderate, severe\]) showing recurrence in follow-up in relation to total number of clinically cleared severe AK lesions 12 weeks after last PDT; overall and stratified by treatment area
Results for this outcome have not been posted.
The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area
Results for this outcome have not been posted.
The esthetic outcome at follow-up visits as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area
Results for this outcome have not been posted.
Satisfaction with PDT treatment after the last PDT as assessed by the subject via questionnaire, 1. if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no) and 2. how they would rate the PDT treatment in comparison to other treatment modalities, if applicable (better than/ similar/ worse). The treatment modalities should be documented, if applicable); overall and stratified by treatment area
Results for this outcome have not been posted.
Relevant AEs include AEs or conditions affecting skin health in the treatment field which may impair proper assessment of the recurrence rate of the treated AK lesions, or other clinically relevant events at the investigator's discretion as well as any SAE that has occurred since the final visit of the treatment phase (Visit 4 or Visit 6); overall and stratified by demographics and treatment area
Results for this outcome have not been posted.
New lesions: AK, non-melanoma skin cancer \[NMSC, including BCC, SCC or BD\] or melanoma
Results for this outcome have not been posted.
Percentage of clinically cleared individual AK target lesions in relation to total number of AK target lesions at baseline (Visit 2) after PDT-1, overall and stratified by treatment area and AK severity at baseline (according to Olsen \[mild, moderate, severe\]).
| Number of Lesions | BF-200 ALA | Vehicle |
|---|---|---|
| Overall | 783 | 89 |
| By Treatment Area: Extremities | 584 | 74 |
| By Treatment Area: Neck/Trunk | 199 | 15 |
| By AK Severity at Baseline: Mild | 522 | 59 |
| By AK Severity at Baseline: Moderate | 261 | 30 |
Percentage of clinically cleared individual severe AK lesions in relation to total number of severe AK lesions at baseline (according to Olsen \[mild, moderate, severe\]; Visit 2) after PDT-1, overall and stratified by treatment area.
| Number of Severe Lesions | BF-200 ALA | Vehicle |
|---|---|---|
| Overall | 1 | 0 |
| By Treatment Area: Extremities | 1 | 0 |
| By Treatment Area: Neck/Trunk | 0 | 0 |
The esthetic appearance after the last PDT as assessed by the investigator according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Overall — Very Good | 67 | 11 |
| Overall — Good | 21 | 6 |
| Overall — Satisfactory | 25 | 5 |
| Overall — Unsatisfactory | 4 | 9 |
| By Treatment Area: Extremities — Very Good | 48 | 7 |
| By Treatment Area: Extremities — Good | 17 | 6 |
| By Treatment Area: Extremities — Satisfactory | 23 | 5 |
| By Treatment Area: Extremities — Unsatisfactory | 4 | 6 |
| By Treatment Area: Neck/Trunk — Very Good | 19 | 4 |
| By Treatment Area: Neck/Trunk — Good | 4 | 0 |
| By Treatment Area: Neck/Trunk — Satisfactory | 2 | 0 |
| By Treatment Area: Neck/Trunk — Unsatisfactory | 0 | 3 |
The esthetic outcome after the last PDT as assessed by the subject according to a 4-point scale ranging from 0 (=very good) to 3 (=unsatisfactory); overall and stratified by treatment area.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Overall — Very Good | 53 | 7 |
| Overall — Good | 30 | 8 |
| Overall — Satisfactory | 26 | 5 |
| Overall — Unsatisfactory | 8 | 11 |
| By Treatment Area: Extremities — Very Good | 41 | 3 |
| By Treatment Area: Extremities — Good | 21 | 7 |
| By Treatment Area: Extremities — Satisfactory | 22 | 5 |
| By Treatment Area: Extremities — Unsatisfactory | 8 | 9 |
| By Treatment Area: Neck/Trunk — Very Good | 12 | 4 |
| By Treatment Area: Neck/Trunk — Good | 9 | 1 |
| By Treatment Area: Neck/Trunk — Satisfactory | 4 | 0 |
| By Treatment Area: Neck/Trunk — Unsatisfactory | 0 | 2 |
Satisfaction with PDT treatment after the last PDT as assessed by the subject; overall and stratified by treatment area. Therefore, subjects were asked if they would chose PDT treatment in the future in case of recurrence or similar disease (yes/no).
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Overall — Subject would choose PDT again | 101 | 26 |
| Overall — Subject would not choose PDT again | 16 | 4 |
| By Treatment Area: Extremities — Subject would choose PDT again | 80 | 19 |
| By Treatment Area: Extremities — Subject would not choose PDT again | 12 | 4 |
| By Treatment Area: Neck/Trunk — Subject would choose PDT again | 21 | 7 |
| By Treatment Area: Neck/Trunk — Subject would not choose PDT again | 4 | 0 |
Frequency and extent of AEs, AESIs, SAEs, and TEAEs, overall and stratified by demographics, skin type class (I-III and IV-VI), size of the treatment field, and treatment area. TEAEs were defined as all AEs starting with or after IMP application and within 12 weeks (+ 7 days) after the last PDT, or as related AEs (possibly, probably, or definitely related, or with missing relationship) occurring more than 12 weeks after the last PDT.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| AEs | 132 | 25 |
| AESIs | 0 | 0 |
| SAEs | 12 | 4 |
| TEAEs | 131 | 25 |
| TEAEs - By age group: 18 - 64 years | 41 | 5 |
| TEAEs - By age group: 65 - 74 years | 57 | 15 |
| TEAEs - By age group: 75 years and older | 33 | 5 |
| TEAEs - By sex: female | 59 | 16 |
| TEAEs - By sex: male | 72 | 9 |
| TEAEs - By Fitzpatrick skin type: Type I - III | 126 | 23 |
| TEAEs - By Fitzpatrick skin type: Type IV - VI | 5 | 2 |
| TEAEs - By Size of treatment field: 80 cm² | 34 | 5 |
| TEAEs - By Size of treatment field: 160 cm² | 50 | 12 |
| TEAEs - By Size of treatment field: 240 cm² | 47 | 8 |
| TEAEs - By treatment area: Extremities | 105 | 18 |
| TEAEs - By treatment area: Neck/trunk | 26 | 7 |
New lesions: AK, non-melanoma skin cancer \[NMSC, including Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC) or Bowen's Disease (BD)\] or melanoma
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| New Lesions Inside the Treatment Field During Treatment Phase | 24 | 6 |
Application site reactions (bleeding, burning, discharge, edema, erosion, erythema, exfoliation, hyperalgesia, induration, irritation, paraesthesia, pruritus, pustules, scabbing, or vesicles) were assessed on a 4-point scale: grade 0 = none, grade 1 = mild, grade 2 = moderate, grade 3 = severe. The worst severity across all assessment timepoints and illumination areas is presented.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Burning — None | 41 | 30 |
| Burning — Mild | 47 | 4 |
| Burning — Moderate | 34 | 0 |
| Burning — Severe | 8 | 0 |
| Hyperalgesia — None | 101 | 33 |
| Hyperalgesia — Mild | 16 | 1 |
| Hyperalgesia — Moderate | 12 | 0 |
| Hyperalgesia — Severe | 1 | 0 |
| Irritation — None | 95 | 32 |
| Irritation — Mild | 21 | 2 |
| Irritation — Moderate | 11 | 0 |
| Irritation — Severe | 3 | 0 |
| Paraesthesia — None | 84 | 31 |
| Paraesthesia — Mild | 32 | 3 |
| Paraesthesia — Moderate | 14 | 0 |
| Paraesthesia — Severe | 0 | 0 |
| Pruritus — None | 69 | 27 |
| Pruritus — Mild | 51 | 7 |
| Pruritus — Moderate | 9 | 0 |
| Pruritus — Severe | 1 | 0 |
| Bleeding — None | 128 | 34 |
| Bleeding — Mild | 1 | 0 |
| Bleeding — Moderate | 1 | 0 |
| Bleeding — Severe | 0 | 0 |
| Discharge — None | 128 | 34 |
| Discharge — Mild | 2 | 0 |
| Discharge — Moderate | 0 | 0 |
| Discharge — Severe | 0 | 0 |
| Edema — None | 97 | 32 |
| Edema — Mild | 24 | 2 |
| Edema — Moderate | 9 | 0 |
| Edema — Severe | 0 | 0 |
| Erosion — None | 117 | 33 |
| Erosion — Mild | 8 | 1 |
| Erosion — Moderate | 1 | 0 |
| Erosion — Severe | 4 | 0 |
| Erythema — None | 30 | 20 |
| Erythema — Mild | 46 | 12 |
| Erythema — Moderate | 42 | 2 |
| Erythema — Severe | 12 | 0 |
| Exfoliation — None | 102 | 33 |
| Exfoliation — Mild | 19 | 1 |
| Exfoliation — Moderate | 5 | 0 |
| Exfoliation — Severe | 4 | 0 |
| Induration — None | 105 | 34 |
| Induration — Mild | 17 | 0 |
| Induration — Moderate | 7 | 0 |
| Induration — Severe | 1 | 0 |
| Pustules — None | 122 | 34 |
| Pustules — Mild | 5 | 0 |
| Pustules — Moderate | 2 | 0 |
| Pustules — Severe | 1 | 0 |
| Scabbing — None | 96 | 33 |
| Scabbing — Mild | 29 | 1 |
| Scabbing — Moderate | 4 | 0 |
| Scabbing — Severe | 1 | 0 |
| Vesicles — None | 118 | 34 |
| Vesicles — Mild | 8 | 0 |
| Vesicles — Moderate | 3 | 0 |
| Vesicles — Severe | 1 | 0 |
Reported by the subjects assessed on an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst imaginable pain); overall and stratified by size of the treatment field and treatment area. The maximum of pain score over all illuminations is shown.
| Pain score | BF-200 ALA | Vehicle |
|---|---|---|
| Overall | 5.4 ± 2.5 | 0.4 ± 0.7 |
| By Treatment Area: Extremities | 5.3 ± 2.4 | 0.4 ± 0.7 |
| By Treatment Area: Neck/Trunk | 5.8 ± 2.7 | 0.3 ± 0.5 |
| By Size of the Treatment Field: 80 cm² | 4.6 ± 2.2 | 0.1 ± 0.3 |
| By Size of the Treatment Field: 160 cm² | 5.1 ± 2.2 | 0.4 ± 0.6 |
| By Size of the Treatment Field: 240 cm² | 6.5 ± 2.6 | 0.5 ± 0.9 |
Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\] and changes in pulse rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Befort treatment start — Clinically significant vital signs reported | 2 | 0 |
| Befort treatment start — No clinically significant vital signs reported | 134 | 36 |
| After treatment start — Clinically significant vital signs reported | 0 | 0 |
| After treatment start — No clinically significant vital signs reported | 136 | 36 |
Changes in clinical chemistry, in hematology and urinalysis parameters as defined in the protocol. Findings which differed from reference range and were considered clinically significant were to be reported.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Befort treatment start — Clinically significant safety laboratory results reported | 1 | 1 |
| Befort treatment start — No clinically significant safety laboratory results reported | 135 | 35 |
| After treatment start — Clinically significant safety laboratory results reported | 1 | 0 |
| After treatment start — No clinically significant safety laboratory results reported | 135 | 36 |
Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.
| Participants | BF-200 ALA | Vehicle |
|---|---|---|
| Befort treatment start — Clinically significant physical examination findings reported | 1 | 0 |
| Befort treatment start — No clinically significant physical examination findings reported | 135 | 36 |
| After treatment start — Clinically significant physical examination findings reported | 1 | 0 |
| After treatment start — No clinically significant physical examination findings reported | 135 | 36 |
Collected over Collection of AEs started with signing the informed consent documents and ended with the end of the treatment phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BF-200 ALA | 0/136 (0%) | 12/136 (8.8%) | 132/136 (97.1%) |
| Vehicle | 0/36 (0%) | 4/36 (11.1%) | 24/36 (66.7%) |
| Event | BF-200 ALA | Vehicle |
|---|---|---|
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/136 | 1/36 |
| Hiatus herniaGastrointestinal disorders | 0/136 | 1/36 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/136 | 1/36 |
| KeratoacanthomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/136 | 1/36 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/136 | 1/36 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/136 | 0/36 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/136 | 0/36 |
| Coronary artery diseaseCardiac disorders | 1/136 | 0/36 |
| Staphylococcal skin infectionInfections and infestations | 1/136 | 0/36 |
| Electrocardiogram abnormalInvestigations | 1/136 | 0/36 |
| Event | BF-200 ALA | Vehicle |
|---|---|---|
| Application site erythemaGeneral disorders | 110/136 | 14/36 |
| Application site painGeneral disorders | 100/136 | 4/36 |
| Application site pruritusGeneral disorders | 73/136 | 8/36 |
| Application site paraesthesiaGeneral disorders | 49/136 | 3/36 |
| Application site exfoliationGeneral disorders | 38/136 | 1/36 |
| Application site oedemaGeneral disorders | 38/136 | 2/36 |
| Application site irritationGeneral disorders | 35/136 | 2/36 |
| Application site scabGeneral disorders | 34/136 | 1/36 |
| Application site hyperaesthesiaGeneral disorders | 30/136 | 1/36 |
| Application site indurationGeneral disorders | 25/136 | 0/36 |
Participants were randomized to the treatment arms in 4:1 ratio.
| Age, Customized(Participants) | BF-200 ALA | Vehicle | Total |
|---|---|---|---|
| Number of Participants Analyzed — 18 - 64 years | 41 | 10 | 51 |
| Number of Participants Analyzed — 65 - 74 years | 60 | 21 | 81 |
| Number of Participants Analyzed — 75 years and older | 35 | 5 | 40 |
| Sex: Female, Male(Participants) | BF-200 ALA | Vehicle | Total |
|---|---|---|---|
| Female | 60 | 20 | 80 |
| Male | 76 | 16 | 92 |
| Race (NIH/OMB)(Participants) | BF-200 ALA | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 136 | 36 | 172 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | BF-200 ALA | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 135 | 36 | 171 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Fitzpatrick Skin Type, Categorical(Participants) | BF-200 ALA | Vehicle | Total |
|---|---|---|---|
| Type I - III | 131 | 33 | 164 |
| Type IV - VI | 5 | 3 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2022 to primary completion in Sep 2025, 32 months.
Results were first posted in Aug 2026, 11 months after primary completion.
Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 32 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biofrontera Inc.